Eledon Pharmaceuticals, Inc.
ELDN
$3.58
$0.00-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.54M | 16.98M | 19.76M | 19.65M | 19.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.47M | 83.25M | 86.46M | 87.90M | 77.67M |
| Operating Income | -86.47M | -83.25M | -86.46M | -87.90M | -77.67M |
| Income Before Tax | -78.11M | -45.58M | -79.36M | 15.07M | -18.62M |
| Income Tax Expenses | 35.00K | 35.00K | 431.00K | 431.00K | 431.00K |
| Earnings from Continuing Operations | -78.15 | -45.62 | -79.79 | 14.64 | -19.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.15M | -45.62M | -79.79M | 14.64M | -19.05M |
| EBIT | -86.47M | -83.25M | -86.46M | -87.90M | -77.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.65 | -0.51 | -1.08 | 1.05 | -0.32 |
| Normalized Basic EPS | -0.41 | -0.32 | -0.65 | 0.42 | -0.15 |
| EPS Diluted | -0.65 | -0.51 | -1.08 | -1.14 | -2.51 |
| Normalized Diluted EPS | -0.41 | -0.32 | -0.65 | 0.36 | -0.21 |
| Average Basic Shares Outstanding | 477.38M | 442.08M | 416.02M | 390.81M | 356.28M |
| Average Diluted Shares Outstanding | 477.38M | 442.08M | 416.02M | 394.34M | 359.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |